Vericiguat: A New Hope for Heart Failure Patients
Heart failure with reduced ejection fraction (HFrEF) is the inability of the heart to adequately contract or eject blood. This heart is unable to produce adequate cardiac output to perfuse vital tissues. At a fundamental level, it is known that the cardioprotective pathway of nitric oxide-soluble gu...
Saved in:
Main Authors: | Raquel Chiles, Rami A. Al-Horani |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-01-01
|
Series: | Cardiovascular Therapeutics |
Online Access: | http://dx.doi.org/10.1155/2022/1554875 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Elevating Expectations: Vericiguat in Heart Failure with Reduced Ejection Fraction
by: Pushpraj Patel, et al.
Published: (2024-12-01) -
Efficacy of vericiguat in patients with chronic heart failure and reduced ejection fraction: a prospective observational study
by: Yinge Zhan, et al.
Published: (2025-02-01) -
Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial
by: Alberto Esteban-Fernández, et al.
Published: (2025-01-01) -
New hope for the world cancer day
by: Gerry Melino, et al.
Published: (2025-02-01) -
Amyloid-β and heart failure in Alzheimer’s disease: the new vistas
by: Hayder M. Al-Kuraishy, et al.
Published: (2025-02-01)